Scott Liebman is leader of the firm's Life Sciences team and is based in the firm’s New York office.
Areas of Practice
Scott focuses on complex FDA regulatory, compliance and legal matters affecting global pharmaceutical, biotechnology and medical device manufacturers. He counsels clients on federal and state requirements and develops legal and regulatory strategies to help commercialize their products.
Clients regularly turn to Scott and his team to support product launches; implement corporate integrity agreements; develop comprehensive training and monitor compliance programs; and handle anti-kickback, sampling and off-label investigations. Whether advising executives or training a national sales force, Scott knows that clear, thoughtful communication and practical advice are key to supporting his clients.
He has worked with businesses of all sizes, from small life sciences organizations launching their first product to Fortune 500 companies in the pharmaceutical and medical products/equipment industries. His clients operate worldwide and include Europe- and Asia-based life sciences companies.
Scott is passionate about understanding his clients’ challenges and is committed to learning their businesses inside and out to find solutions. He brings deep technical knowledge along with enthusiasm for his clients’ work to each client relationship.
Leading Life Sciences Lawyer - FDA Medical Device and FDA Pharmaceutical, LMG Life Sciences, 2021-2022
Health Care Trailblazer, The National Law Journal, 2020
Rising Star, the New York Law Journal, 2014
New Leaders of The Bar, New Jersey Law Journal, 2012
New York Metro Rising Star in Health Care Law, Thomson Reuters, 2014-2015
New Jersey Rising Star in Health Care Law, Thomson Reuters, 2013
- Law360, 01.11.2023
- Industry Fights Back Against Restrictions on Pharmaceutical Manufacturers’ Ability To Offer Drug Cost-Sharing SubsidiesNew York Law Journal, 01.09.2023
- New York Law Journal, 03.23.2022
FDA Law Blog Posts
- "OIG General Compliance Program Guidance November 2023," November 8, 2023
- "OIG Advisory Opinion Alert: Yet Another Favorable Decision for Medical Device Manufacturers," March 17, 2022
- May 17-18, 2023